BRCA1 and ovarian carcinoma: Furthermore, resistance to taxane containing regimens have been documented in serous high-grade ovarian carcinomas displaying BRCA1/2 germline mutations (Hennessy et al. 2010; Mafficini et al. 2016; Moschetta et al. 2016; Muggia 2009; Oza et al. 2015; Kwon et al. 2010; Muggia et al. 2011).